Efficacy & Safety of a Purified Standardised Bee Venom Preparation

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Bee Venom Allergy

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT04259359` - Predominant Sensitizations to Single Bee Venom Allergens as a Risk Factor for Therapy Failure
	Completed	`NCT04435678` - Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens	N/A

See also

Status

Clinical Trial

Phase

Recruiting

NCT04259359 - Predominant Sensitizations to Single Bee Venom Allergens as a Risk Factor for Therapy Failure

Completed

NCT04435678 - Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens

N/A

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT00263952
Study type	Interventional
Source	Allergopharma GmbH & Co. KG
Contact
Status	Completed
Phase	Phase 3
Start date	March 2003
Completion date	April 2010

Efficacy and Safety of a Purified Standardised Bee Venom Preparation

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms